Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKYLINE-UC: Platform Trial of SPY001, SPY002, and SPY003 in Ulcerative Colitis
NCT07012395Phase 2Recruiting
- Sponsor
- Spyre Therapeutics, Inc.
- Start
- May 2025
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 35
01
Overview
Phase 2, randomised, double-blind trial of SPY001, SPY002 and SPY003 in ulcerative colitis (UC) (13 arms), sponsored by Spyre Therapeutics, Inc. Primary endpoints: Change in Robarts Histopathology Index at 12 weeks and Percentage of participants with clinical remission at 12 weeks. Started May 2025; status: recruiting.
02
Drugs
SPY001SPY002SPY003
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07012395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07012395.